Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. investors.elevationoncology.comElevation Oncology | Investor Overview

    7 de may. de 2024 · Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements -- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- --...

    • News Releases

      Elevation Oncology Reports Fourth Quarter and Full Year 2023...

  2. investors.elevationoncology.com › 2022/11/03-Elevation-Oncology-Reports-ThirdBrowse our latest resources - Elevation Oncology Investors

    3 de nov. de 2022 · NEW YORK, Nov. 3, 2022 / PRNewswire / -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced financial results for the quarter ended September 30, 2022, and highlighted recent progress.

  3. elevationcapital.comElevation – Elevation

    We build long lasting personal relationships by giving individual time and attention to every founder. Paytm. "Elevation was our first institutional investor and our relationship has transcended from that of investor and investee to business partners and great friends." Read the Paytm story. Bookmyshow.

  4. investors.elevationoncology.com › 2024/03/06-Elevation-Oncology-Reports-FourthElevation Oncology Reports Fourth Quarter and Full Year 2023...

    6 de mar. de 2024 · BOSTON, March 6, 2024 / PRNewswire / -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended Decembe...

  5. elevationgold.comHome | Elevation Gold Mining Corp.

    Latest News. Read All News. Elevation Gold Reports Financial Results for Year Ended December 31, 2023, including $66.4M in Total Revenue Read More. Elevation Gold Reports Claim by Royalty Holder Read More. Elevation Gold Reports Q1 2024 Production Results and Provides Update on Liquidity and Other Corporate Matters Read More.

  6. investors.elevationoncology.com › 2024/01/05-Elevation-Oncology-AnnouncesElevation Oncology Announces Program Updates and Upcoming 2024...

    5 de ene. de 2024 · Jan 5, 2024. Corporate. -- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting ADC as Second Pipeline Program; Development Candidate Nomination in 2024--